FBLG

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing cell-based therapies using fibroblast cells. The company's proprietary platform technology leverages the regenerative properties of fibroblasts to treat degenerative diseases, cancer, and wound healing applications. FibroBiologics is developing a pipeline of therapeutic candidates targeting conditions including multiple sclerosis, degenerative disc disease, and various oncology indications. The company's approach seeks to harness the immunomodulatory and tissue-regenerative capabilities of fibroblast cells to address unmet medical needs across multiple therapeutic areas.